Unique platform technology with initial proof-of-concept
Addressing a common thread across many age-related disorders
Many age-related diseases share impaired local blood flow as a fundamental underlying mechanism, which limits the supply of oxygen and nutrients to tissues. This vascular dysfunction contributes to tissue degeneration, impaired repair processes, and the progression of chronic conditions.
DualTOP™: Unique mechanism of action to restore circulation and reactivate healing
Topadur Pharma’s DualTOP™ platform is a breakthrough approach that targets the cyclic guanosine monophosphate (cGMP) signaling cascade, a central regulator of blood vessel function and tissue regeneration. DualTOP™ drugs combine two synergistic effects: they stimulate the production of cGMP while at the same time blocking its breakdown. This dual action sustains high cGMP levels, directly improving blood flow where it is needed most and supporting the body’s own repair processes.
Want to go deeper?
For detailed insights into the biology and data that validate our platform, see our publication: Naef et al., 2020 – “TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.”
Local action for lasting impact across multiple high-need indications
Delivered directly to the site of disease, Topadur’s therapies achieve potent, localized activity while minimizing systemic exposure and reducing side effects. From systemic sclerosis and diabetic foot ulcers, to alopecia and colorectal cancer, our DualTOP™ platform has already shown compelling promise in both preclinical studies and clinical trials.
Validated biology with versatile potential
In a Phase 1 clinical trial, our lead compound TOP-N53 demonstrated an excellent safety profile and tolerability, with promising exploratory evidence supporting improved skin blood flow. Together with strong preclinical data across multiple tissues and disease models, this underscores the potential and broad therapeutic opportunities for our DualTOP™ platform.